Kura Oncology, Inc. (KURA) Dividend History

Company News

• Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

  Kura Oncology and Kyowa Kirin announced positive pivotal data from the KOMET-001 Phase 2 trial of ziftomenib, an investigational menin inhibitor, in patients with relapsed/refractory NPM1-mutant acute myeloid leukemia. The data showed a 23% complete remission/complete remission with partial hematological recovery rate and a favorable safety profile.

  GlobeNewswire Inc.
• Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

  Kura Oncology and Kyowa Kirin announced that the FDA has accepted their New Drug Application for ziftomenib, a menin inhibitor, for the treatment of adult patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. The application has been granted Priority Review with a target action date of November 30, 2025.

  GlobeNewswire Inc.
• Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

  Kura Oncology and Kyowa Kirin announced positive results from the KOMET-001 trial of ziftomenib, an investigational menin inhibitor, in relapsed/refractory NPM1-mutant acute myeloid leukemia. The data will be presented at the 2025 ASCO Annual Meeting.

  GlobeNewswire Inc.
• Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

  Kura Oncology announced the publication of its KOMET-001 Phase 1 study results in The Lancet Oncology, demonstrating promising clinical activity and manageable toxicity of its investigational drug ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).

  GlobeNewswire Inc.
• Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

  – Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –

  GlobeNewswire Inc.